Department of Neurology, Medical Faculty Mannheim and Mannheim Center of Translational Neurosciences (MCTN), Heidelberg University, Mannheim, Germany.
Department of Neurology, Medical Faculty Mannheim and Mannheim Center of Translational Neurosciences (MCTN), Heidelberg University, Mannheim, Germany/German Consortium of Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mult Scler. 2022 Dec;28(14):2294-2298. doi: 10.1177/13524585221106338. Epub 2022 Jul 1.
We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT ( = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.
我们使用一种新的磁共振成像（MRI）后处理方法 T1/T2 比值，研究了疾病修正疗法（DMT）对铁环多发性硬化病变中不断发展的组织损伤的影响。在这项研究中，在基线和 1 年随访时，开始 DMT（富马酸二甲酯、芬戈莫德、奥瑞珠单抗）的患者的铁环病变（IRL）的 T1/T2 比值与未接受 DMT 的患者相比没有统计学差异。在第二次随访时，未接受 DMT 的患者的 IRL 中的 T1/T2 比值显著降低（=0.002），表明 DMT 对 IRL 中的病变演变和组织基质损伤具有有益的延迟作用。
